{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:56:42Z","timestamp":1773867402606,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.euroneuro.2009.02.006","type":"journal-article","created":{"date-parts":[[2009,4,3]],"date-time":"2009-04-03T08:40:29Z","timestamp":1238748029000},"page":"476-482","source":"Crossref","is-referenced-by-count":25,"title":["Zolmitriptan compared to propranolol in the treatment of acute neuroleptic-induced akathisia: A comparative double-blind study"],"prefix":"10.1016","volume":"19","author":[{"given":"Ayelet","family":"Avital","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Gross-Isseroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Stryjer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haggai","family":"Hermesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni","family":"Shiloh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.02.006_bib1","first-page":"21","article-title":"Noradrenergic mechanism in akathisia: treatment with propranolol and clonidine","volume":"23","author":"Adler","year":"1987","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib2","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"1021","key":"10.1016\/j.euroneuro.2009.02.006_bib3","first-page":"27","article-title":"Zolmitriptan for migraine","volume":"40","author":"Anon","year":"1998","journal-title":"Med. Lett."},{"issue":"17","key":"10.1016\/j.euroneuro.2009.02.006_bib4","first-page":"44","article-title":"Zolmitriptan appears effective in menstrual migraine patients: significant, sustained relief","volume":"33","author":"Anon","year":"2003","journal-title":"Family Practice News"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/014107688507800910","article-title":"Drug-induced akathisia: a review","volume":"78","author":"Ball","year":"1985","journal-title":"J. Royal Soc. Med."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale \u2014 revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"Suppl 38","key":"10.1016\/j.euroneuro.2009.02.006_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1192\/S0007125000298097","article-title":"Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics","author":"Barnes","year":"1999","journal-title":"Br. J. Psychiatry"},{"issue":"suppl","key":"10.1016\/j.euroneuro.2009.02.006_bib9","first-page":"25","article-title":"Pathophysiology of antipsychotic drug-induced movement disorders","volume":"65","author":"Casey","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0333102497017S1803","article-title":"The clinical pharmacokinetics of zolmitriptan","volume":"17","author":"Dixon","year":"1997","journal-title":"Cephalalgia"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-2982.2004.00647.x","article-title":"Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain","volume":"24","author":"Dobson","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1468-2982.2004.00694.x","article-title":"Triptans and CNS side effects: pharmacokinetic and metabolic mechanisms","volume":"24","author":"Dodick","year":"2004","journal-title":"Cephalalgia"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000119097","article-title":"Clinical safety of 311C90: aggregated data from patients and volunteers to date","volume":"36","author":"Earl","year":"1996","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib14","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT 1b\/1d agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00004714-200112000-00013","article-title":"Cyproheptadine versus propranolol for the treatment of acute neuroleptic induced akathisia: a comparative double blind study","volume":"21","author":"Fischel","year":"2001","journal-title":"J. Clinical. Psychophrm."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199002000-00003","article-title":"The pharmacologic treatment of neuroptic induced akathisia","volume":"10","author":"Fleischhacker","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"issue":"suppl 2","key":"10.1016\/j.euroneuro.2009.02.006_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000119100","article-title":"Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine","volume":"36","author":"Geraud","year":"1996","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004850-200501000-00005","article-title":"The 5HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open-label preliminary study","volume":"20","author":"Gross-Isseroff","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neuros. Psych."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib22","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.annemergmed.2007.03.012","article-title":"Should anticholinergics drugs be used for neuroleptic induced acute akathisia?","volume":"50","author":"Koertner","year":"2007","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.v57n1002","article-title":"Movement disorders associated with the serotonin selective reuptake inhibitors (review)","volume":"57","author":"Leo","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/ajp.141.3.412","article-title":"Propranolol in the treatment of neuroleptic induced akathisia","volume":"141","author":"Lipinski","year":"1984","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S003329170003960X","article-title":"The pathophysiology of extra-pyramidal side effects of neuroleptic drugs","volume":"10","author":"Marsden","year":"1980","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib27","first-page":"373","article-title":"Treatment of neuroleptic induced akathisia with the 5HT-2 antagonist Ritanserine","volume":"26","author":"Miller","year":"1990","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1192\/bjp.161.6.735","article-title":"Fluoxetine and suicidal behaviour: some clinical and theoretical aspects of a controversy","volume":"161","author":"Power","year":"1992","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.174.3.238","article-title":"Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin: double blind, placebo controlled study","volume":"174","author":"Poyurovsky","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopsych.2005.12.007","article-title":"Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo and propranolol controlled trial","volume":"59","author":"Poyurovsky","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/schbul\/21.3.431","article-title":"The epidemiology of drug-induced akathisia: part I","volume":"21","author":"Sachdev","year":"1995","journal-title":"Acute akathisia. Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-7634(99)00069-X","article-title":"Animal models of acute drug-induced akathisia \u2014 a review","volume":"24","author":"Sachdev","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005053-199107000-00001","article-title":"The present status of akathisia","volume":"179","author":"Sachdev","year":"1991","journal-title":"J. Nerv. Ment. Dis."},{"issue":"1","key":"10.1016\/j.euroneuro.2009.02.006_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psc.2004.10.004","article-title":"Neuroleptic-induced movement disorders: an overview","volume":"28","author":"Sachdev","year":"2005","journal-title":"Psychiatr. Clin. North. Am."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extra-pyramidal side effects","volume":"213","author":"Simpson","year":"1970","journal-title":"Acta. Psychiatry Scand."},{"issue":"4","key":"10.1016\/j.euroneuro.2009.02.006_bib36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0025-7125(05)70353-9","article-title":"Safety and rational use of the triptans","volume":"85","author":"Tepper","year":"2001","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/14740338.2.2.123","article-title":"Safety profile of the triptans (review)","volume":"212","author":"Tepper","year":"2003","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2009.02.006_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1526-4610.2003.03007.x","article-title":"Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients","volume":"43","author":"Tepper","year":"2003","journal-title":"Headache"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1468-2982.1996.1604270.x","article-title":"311C90 (zolmitriptan\u204e), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period","volume":"16","author":"Thomsen","year":"1996","journal-title":"Cephalalgia"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib40","series-title":"US Food and Drug Administration. Rockville","article-title":"5-Hydroxytryptamine Receptor Agonists (Triptans) Selective Serotonin Reuptake Inhibitors (SSRIs) Selective Serotonin\/Norepinephrine Reuptake Inhibitors (SNRIs) Serotonin Syndrome","author":"US Food and Drug Administration","year":"2006"},{"key":"10.1016\/j.euroneuro.2009.02.006_bib41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.167.4.483","article-title":"Cyproheptadine treatment in neuroleptic induced akathisia","volume":"167","author":"Weiss","year":"1995","journal-title":"Br. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T21:00:43Z","timestamp":1739048443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0924977X09000674"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.02.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}